Compare SMTI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | ENLV |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.6M | 196.2M |
| IPO Year | 2008 | 2014 |
| Metric | SMTI | ENLV |
|---|---|---|
| Price | $19.15 | $0.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $34.00 | $20.00 |
| AVG Volume (30 Days) | 34.8K | ★ 524.5K |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $17.31 | N/A |
| Revenue Next Year | $12.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $0.66 |
| 52 Week High | $35.70 | $2.10 |
| Indicator | SMTI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 41.23 |
| Support Level | $18.60 | $0.79 |
| Resistance Level | $21.26 | $1.23 |
| Average True Range (ATR) | 1.00 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.52 | 28.99 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.